Chris Sandburg
Recent Articles by Chris Sandburg
- Veru’s (NASDAQ: VERU) Repurposed COVID-19 Drug Facing Uphill Battle for EUA
- CytoDyn (CYDY) Board Starts Anew with Dramatic Cleaning of the Top Leadership
- Todos (OTCMKTS: TOMDF) CEO Nails NewsMax Interview With Critical Messages About the Pandemic
- CytoDyn (OTCMKTS: CYDY): A Biotech Under Seige or Preparing for a Counter Attack?
- Why Todos Medical (OTCMKTS: TOMDF) is Running Ahead of the Pack
- The 3CL Secret to Pfizer's and Todos Medical’s Success
- Picking a Bottom in CytoDyn - Right Now
- Atea Failure Leaves Todos Medical (TOMDF) Last Man Standing in Oral Antivirals
- Todos Medical (TOMDF) COVID-19 Oral Antiviral Takes Death off Table
- Moderna’s (MRNA) Bloated Market Cap & mRNA Vaccine Thesis Under Fire
Recent Comments by Chris Sandburg
- "The essence of your argument seems to be centered around expectations. NP has clearly missed some self imposed deadlines, but these misses pale in co" on CytoDyn’s Preliminary Phase 1b/2 Cancer Results Likely to Receive Breakthrough Therapy Designation (BTD)